Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sarepta Therapeutics Inc    SRPT

SAREPTA THERAPEUTICS INC

(SRPT)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/11/2019 09/12/2019 09/13/2019 09/16/2019 09/17/2019 Date
89.08(c) 87.98(c) 86(c) 87.02(c) 84.88(c) Last
1 329 068 1 201 140 1 057 088 928 822 1 578 897 Volume
-2.19% -1.23% -2.25% +1.19% -2.46% Change
More quotes
Financials (USD)
Sales 2019 381 M
EBIT 2019 -543 M
Net income 2019 -539 M
Finance 2019 533 M
Yield 2019 -
Sales 2020 489 M
EBIT 2020 -350 M
Net income 2020 -367 M
Finance 2020 450 M
Yield 2020 -
P/E ratio 2019 -11,4x
P/E ratio 2020 -17,3x
EV / Sales2019 15,2x
EV / Sales2020 12,0x
Capitalization 6 310 M
More Financials
Company
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to... 
More about the company
Surperformance© ratings of Sarepta Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on SAREPTA THERAPEUTICS INC
09/16BRAGAR EAGEL & SQUIRE, P.C. ANNOUNCE : SRPT) and Encourages Sarepta Investors to..
BU
09/13LEAD PLAINTIFF DEADLINE ALERT : Faruqi & Faruqi, LLP Encourages Investors Who Su..
NE
09/08LEAD PLAINTIFF DEADLINE ALERT : Faruqi & Faruqi, LLP Encourages Investors Who Su..
NE
09/06IMPORTANT INVESTOR REMINDER : The Schall Law Firm Announces the Filing of a Clas..
BU
09/05LEAD PLAINTIFF DEADLINE ALERT : Faruqi & Faruqi, LLP Encourages Investors Who Su..
NE
09/05The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sa..
BU
09/05Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarsh..
GL
09/04SHAREHOLDER ALERT - SAREPTA THERAPEU : October 29, 2019
PR
09/03Sarepta Therapeutics to Present at the Morgan Stanley 17th Annual Global Heal..
GL
09/02SAREPTA THERAPEUTICS : Announces Inducement Grants Under Nasdaq Listing Rule 563..
AQ
More news
Analyst Recommendations on SAREPTA THERAPEUTICS INC
More recommendations
Sector news : Bio Therapeutic Drugs
09/16A Plan to Fight Hep C -- WSJ
DJ
09/03Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals
RE
08/29GLOBAL MARKETS LIVE : Dell, United Airlines, UBS, Apple…
08/28U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight
RE
08/28US Judge Mostly Sets Aside Jury Ruling on Repatha Patents -Reuters
DJ
More sector news : Bio Therapeutic Drugs
Chart SAREPTA THERAPEUTICS INC
Duration : Period :
Sarepta Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAREPTA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Average target price 188,32  $
Last Close Price 84,88  $
Spread / Highest target 218%
Spread / Average Target 122%
Spread / Lowest Target 53,2%
EPS Revisions
Managers
NameTitle
Douglas S. Ingram President, Chief Executive Officer & Director
M. Kathleen Behrens Chairman
Sandesh Mahatme Executive VP, Chief Financial & Business Officer
Guriqbal S. Basi Chief Scientific Officer
Gilmore O’Neill Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
SAREPTA THERAPEUTICS INC-22.22%6 310
GILEAD SCIENCES5.79%83 434
VERTEX PHARMACEUTICALS6.21%45 637
REGENERON PHARMACEUTICALS-22.86%31 283
GENMAB27.92%13 184
NEUROCRINE BIOSCIENCES, INC.42.01%8 956